Public Device & Biopharma Ophthalmology Company Showcase - Omeros at OIS@AAO 2016. Presenter: Leonard M. Blum, Chief Business & Commercial Officer Powered by: Healthegy For more ophthalmology innovation Visit us at www.ois.net

1. 1
Next-Generation Therapeutics
Transforming Patient Care Today
Leonard M. Blum
Chief Business and Commercial Officer
Ophthalmology Innovation Summit
Chicago, IL
October 13, 2016

2. 2
Safe Harbor
This presentation contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on the current intent and
expectations of the management of Omeros Corporation. These
statements are not guarantees of future performance and involve risks
and uncertainties that are difficult to predict. Omeros’actual results
and the timing and outcome of events may differ materially from those
expressed in or implied by the forward-looking statements because of risks
associated with Omeros’unproven preclinical and clinical development
activities, regulatory oversight, product commercialization, intellectual
property claims, competitive developments, litigation and other factors.
For additional information about the factors that affect the company's
business, please see the company's latest Forms 10-K and 10-Q filed with
the Securities and Exchange Commission. Except as required by law,
Omeros undertakes no obligation to update any forward-looking
statements in this presentation, whether as a result of new information,
future events or otherwise.

3. 3
Ophthalmic Surgery: OMIDRIA®
 Intraocular product to prevent miosis and
to reduce postoperative ocular pain in
adults undergoing cataract surgery or
refractive lens exchange
 NSAID-containing product for intraocular
administration during cataract surgery
OMIDRIA is the first and only FDA-approved…

4. 4
Early Focus at Launch:
Patient Access to OMIDRIA®
 OMIDRIA was granted pass-through status by CMS
– Paid separately (ASP + 6%) outside of the facility’s packaged
payment for cataract surgery
– Budget-neutral to the healthcare system
 Covered and reimbursed by 100% of Medicare Administrative
Contractors
 Expanding coverage by Medicare Advantage plans and
commercial payers
Patient access further expanded through OMIDRIAssure™
and 340b programs

5. 5
OMIDRIA® Net Revenue
3Q 2015
4Q 2015
1Q 2016
2Q 2016
$3.2 M
$6.7 M
$7.2 M
$10.0 M
Net Revenue by Quarter

6. 6
OMIDRIA® Real-World Evidence
Shows Improved Outcomes
 Decrease in complications
associated with small pupils1
 Reduction in usage of pupil-
expanding devices1-3
 Prevention of miosis during
femtosecond laser-assisted surgery4
 Shorter surgical times1,2
 Improvement in uncorrected visual
acuity on postoperative Day 11
1. Rosenberg E, et al. Abstract presented at 2016 American Society of Cataract and Refractive Surgeons. 2016. 2. Visco D. Abstract presented
at 2016 American Society of Cataract and Refractive Surgeons. 2016. 3. Bucci F. Abstract presented at 2016 Association for Research in Vision
and Ophthalmology. 2016. 4. Gayton J, et al. Manuscript submitted for publication.
Post-launch,
case-controlled,
single-center analyses,
with and without
femtosecond laser,
resulted in statistically
significant . . .
Additional manuscripts in preparation include effects of OMIDRIA on
prostaglandin inhibition and need for topical NSAIDs

7. 7
Marketed OMIDRIA® Driving the Pipeline
Product/Program Targeted Disease Pre-clinical Phase 1 Phase 2 Phase 3
Marketing
Approval
Economic
Rights
Clinical Programs
MASP-2 (OMS721) -
Lectin Pathway Disorders
Atypical Hemolytic Uremic
Syndrome
MASP-2 (OMS721) -
Lectin Pathway Disorders
IgA Nephropathy and Other
Renal Diseases; TMAs
PDE10 (OMS824) - CNS Disorders Huntington's and Schizophrenia
PPARγ (OMS405) - Addiction Opioid and Nicotine Addiction
OMS201 - Urology Ureteroscopy
Preclinical Programs
PDE7 (OMS527) - CNS Disorders
Addictions and Compulsive
Disorders; Movement Disorders
Plasmin (OMS616) - Bleeding Disorders Surgical and Traumatic Bleeding
MASP-3 (OMS906) – Alternative Pathway
Disorders
PNH and a Wide Range of Other
Alternative Pathway Disorders
GPR17, GPR101, GPR151, GPR161,
GPR174, GPR183
Demyelinating Disorders; Eating
Disorders; Pain; Breast Cancer;
Osteoporosis and EBV; T-Regs
GPCR Platform
CNS, Metabolic, CV, Oncologic,
Musculoskeletal & Other Disorders
Antibody Platform
Metabolic, CV, Oncologic,
Musculoskeletal & Other Disorders

8. 8
OMS721 Targets Mannan-Binding Lectin-Associated Serine
Protease-2, the Effector Enzyme of the Lectin Pathway
Classical Pathway
Alternative
Pathway
Coagulation
Lectin Pathway
Platelet Activation
Leukocyte Recruitment
Cell Lysis
Immune Complex Infection, Tissue Injury
C3a
Factor D
Thrombin
OMS721
MASP-2C1r/s
C4, C2
C4b/2a
C3 C3b
Factor B
C5a
MAC*
C5b
C1q MBL*, Ficolins, CL-11
C5
*MAC = membrane attack complex
*MBL = mannose-binding lectin
OMS721
Phase 3
 Atypical hemolytic
uremic syndrome
(aHUS)
Phase 2
 Complement-associated
nephropathies
 Thrombotic
microangiopathies
Ophthalmic Indications
 AMD
 Uveitis
 Diabetic macular edema

9. 9
Next-Generation Therapeutics
Transforming Patient Care Today
Leonard M. Blum
Chief Business and Commercial Officer
Ophthalmology Innovation Summit
Chicago, IL
October 13, 2016

10. 10